Bias in benefit-Risk appraisal in older products: The case of buflomedil for intermittent claudication

Drug Safety

Volumn 32, Issue 4, 2009, Pages 283-291

  De Backer, Tine L M ^a,b   Vander Stichele, Robert H ^a   Van Bortel, Luc M ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BUFLOMEDIL;

ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INTERMITTENT CLAUDICATION; MORTALITY; NEUROTOXICITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; HUMANS; INTERMITTENT CLAUDICATION; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLICATION BIAS; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; VASODILATOR AGENTS;

EID: 65949103867     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932040-00003     Document Type: Article

References (45)

1. European Medicines Agency. Inspections: good clinical practice [online]. Available from URL: http://www.emea.europa.eu/Inspections/GCPgeneral.html [Accessed 2008 Nov 20]
2. Buflomé dil: attention au surdosage! Rev Prescrire 1998; 18 (181): 115
3. Vingtiè mes journé es françaises de pharmacovigilance: les faits marquants. Rev Prescrire 1999; 19 (197): 519-21
4. Leizorovicz A, Becker F. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebocontrolled, 4-year study. Circulation 2008 Feb 12; 117 (6): 816-22
5. Vial T. Severe adverse effects and acute poisonings caused by buflomedil. Fundam Clin Pharmacol 2006; 20 (2): 145-234
6. De Backer T, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev 2008; (1): CD000988
7. Trü bestein G, Balzer K, Bisler H, et al. Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 1984; 35: 500-5
8. Diamantopoulos EJ, GrigoriadouM, Ifanti G, et al. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Int Angiol 2001 Dec; 20 (4): 337-44
9. Bisler H. Klinische Erfolge der Buflomediltherapie bei arterieller Verschlusskrankheit. Therapiewoche 1983; 33: 2204-10
10. Lowe GDO, Dandona P, Horrocks M, et al. Evaluation of the clinical efficacy and safety of oral buflomedil hydrochloride in the treatment of intermittent claudication. Study QL/UK.83/2-5. Abbott Park (IL): Abbott Laboratories, 1987. (Data on file)
11. Zinnagl N. A double-blind study of the effects of buflomedil in 40 patients with arterial occlusive disease in Stage IIB. International Symposium on Conservative Therapy of Arterial Occlusive Disease; 1986 May 23-25; Bonn. New York: George Thieme Verlag, 1986: 90-91
12. Fonseca V, Mikhailidis DP, Barradas MA, et al. Doubleblind, placebo-controlled trial of buflomedil in intermittent claudication. Int J Clin Pharmacol Res 1988; 8 (5): 377-81
13. Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundam Clin Pharmacol 1995; 9 (4): 387-94
14. Conte MS. Buflomedil in peripheral arterial disease: trials and tribulations. Circulation 2008 Feb 12; 117 (6): 717-9
15. De Backer T, Vander Stichele R, Van Bortel L. Letter by De Backer et al regarding article "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebocontrolled, 4-year study". Circulation 2008; 118: e151
16. Vigibase (the database of the WHO Programme for International Drug Monitoring). Buflomedil ADR: profile PR45-2007. Uppsala: Uppsala Monitoring Center, 2007 Oct 2
17. FDA. Guideline for industry clinical safety data management: definitions and standards for expedited reporting [online]. Available from URL: http://www.fda.gov/cder/guidance/iche2a.pdf [Accessed 2008 Apr 14]
18. European Medicines Agency. ICH topic E 2 B (R3): data elements for transmission of individual case safety reports [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ich/16678305en.pdf [Accessed 2009 Mar 26]
19. Meyboom RHB, Royer RJ. Causality classification in pharmacovigilance centres in the European Community.Pharmacoepidemiol Drug Saf 1992; 1: 87-97
20. Meyboom RHB. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1197; 17 (6): 374-89
21. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Safety 1994; 10 (2): 93-102
22. Abbott. Report of the MAH to the Belgian authorities for a hearing with the Commission of Medicinal Products for Human Use on April 20, 2007. Brussels: Abbott Laboratories, 2007. (Data on file)
23. Medernach C, Garnier R, Efthymiou ML. Acute poisoning by buflomedil. Nouv Presse Med 1981 Nov 21; 10 (42): 3496
24. Athanaselis S, Maravelias C, Michalodimitrakis M, et al. Buflomedil concentrations in blood and viscera in a case of fatal intoxication. Clin Chem 1984 Jan; 30 (1): 157
25. Danel V, Saviuc P, Vincent F, et al. Acute fatal poisoning with buflomedil. J Toxicol Clin Exp 1988 Jul; 8 (4): 243-6
26. Cochard G, Tanguy L, Dubois A, et al. Fatal suicide by buflomedil poisoning. Presse Med 1991 Nov 2; 20 (35): 1739-40
27. Denk R, Raff I, Sachs H. Tö dlicher Verlauf einer Intoxication mit Buflomedil. Münch Med Wschr 1991; 133: 680-2
28. De Giovanni N, Fucci N. Gas chromatographic-mass spectrometric analysis of buflomedil hydrochloride in biological samples after acute intoxication. Forensic Sci Int 1991 Oct; 51 (1): 125-9
29. Ghysel MH, Haguenoer JM. Three cases of fatal intoxication by buflomedil associated with alcohol or paracetamol. Proceedings of the 29th International Meeting of the TIAFT; 1991 Jun 24-27; Copenhagen, 435-9
30. Blery C, Douet N, Fleureaux O, et al. Poisoning by buflomedil (Fonzylane). Cah Anesthesiol 1992; 40 (2): 129-30
31. Goulle JP, Droy JM, Moritz F, et al. Severe intoxications by buflomedil: 2 cases. Presse Med 1995 Jun 17; 24 (22): 1048
32. Piriou V, Jacques D, Guerin C, et al. Severe acute buflomedil poisoning. Ann Fr Anesth Reanim 1995; 14 (5): 432-4
33. Tracqui A, Deveaux M, Kintz P, et al. A fatal case of buflomedil self-poisoning: toxicological data and literature review. Forensic Sci Int 1995 Jan 21; 71 (1): 43-9
34. Tomassini E, Poussel JF, Guiot P. Fatal poisoning caused by buflomedil. Ann Fr Anesth Reanim 1999 Dec; 18 (10): 1091-2
35. Martinez-Sierra R, Lara B, Torres A. Buflomedil intoxication: the little-known risk. J Toxicol Clin Toxicol 1992; 30 (2): 305-8
36. Vandemergel X, Biston P, Lenearts L, et al. Buflomedil poisoning: a potentially life-threatening intoxication. Intensive Care Med 2000 Nov; 26 (11): 1713
37. Neri C, Barbareschi M, Turrina S, et al. Suicide by buflomedil HCl: a case report. J Clin Forensic Med 2004 Feb; 11 (1): 15-6
38. Babel B, Tatschner T, Patzelt D. Suicidal buflomedil intoxication. Arch Kriminol 2004 Mar; 213 (3-4): 108-13
39. ChambostM, Bessas A, Jault V, et al. Acute fatal buflomedil intoxication: clinical and autopsic reports. JEUR 2007; 20 (1): 3-6
40. Rogers AS, Israel E, Smith CR, et al. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med 1988 Jul; 148 (7): 1596-600
41. Heeley E, Waller P, Moseley J. Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study. Drug Saf 2005; 28 (10): 901-6
42. Waller P, Heeley E, Moseley J. Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf 2005; 28 (10): 843-50
43. Heads of Medicines Agencies. Questions and answers on the EU synchronisation of PSUR submission schemes of medicinal products authorised through national, mutual recognition and decentralised procedures, rev1, 21-02-2007 [online]. Available from URL: http://www.hma.eu/195.html[Accessed 2008 Apr 22]
44. Alberti A, Valenti S, Gallo F, et al. Acute buflomedil intoxication: a life-threatening condition. Intensive Care Med 1994; 20 (3): 219-21
45. Gueugniaud PY, Roux H, Petit P. Acute buflomedil intoxication: a critically life-threatening condition. Intensive Care Med 1995 May; 21 (5): 463-4